Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer

References

• Massano J, Regateiro F, Januario G, Ferreira A. Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 67–76
   PubMed Web of Science ®Google Scholar
• Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001; 61: 3272–5
   PubMed Web of Science ®Google Scholar
• Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A, Ries J, Wiltfang J, et al. Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 2006; 132: 219–22
   PubMed Web of Science ®Google Scholar
• Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, et al. Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 2006; 42: 888–92
   PubMedGoogle Scholar
• Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, et al. The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. EJSO (in press).
   Google Scholar
• Jackson A, Brown K, Langdown J, Luddington R, Baglin T. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Haematol 2000; 111: 562–4
   PubMedGoogle Scholar
• Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R. Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet Cytogen 2004; 155: 42–6
   PubMedGoogle Scholar
• Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 2004; 202: 330–5
   PubMed Web of Science ®Google Scholar
• Haiman C, Henderson S, Bretsky P, Kolonel L, Henderson B. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: The multiethnic cohort. Cancer Res 2003; 63: 6984–7
   PubMed Web of Science ®Google Scholar
• Chung FM, Yang YH, Chen CH, Lin CC, Shieh TY. Angiotensin-converting enzyme gene insertion/deletion polymorphism is associated with risk of oral precancerous lesion in betel quid chewers. Br J Cancer 2005; 93: 602–6
   PubMedGoogle Scholar
• Rocken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 2005; 11: 2526–30
   PubMed Web of Science ®Google Scholar
• Stroth U, Unger T. The renin angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33: 21–8
   PubMed Web of Science ®Google Scholar
• Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294: 441–7
   PubMed Web of Science ®Google Scholar
• Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98: 29–35
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Yoshii J, IkenakaY, Yoshiji H, Noguchi R, Yanase K, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002;20:1227–31.
   PubMed Web of Science ®Google Scholar
• McKenzie CA, Julier C, Forrester T, McFarlane-Anderson N, Keavney B, Lathrop GM, et al. Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: Evidence for two quantitative-trait loci. Am J Hum Genet 1995; 57: 1426–35
   PubMed Web of Science ®Google Scholar
• Zhu X, McKenzie CA, Forrester T, Nickerson DA, Broeckel U, Schunkert H, et al. Localization of a small genomic region associated with elevated ACE. Am J Hum Genet 2000; 67: 1144–53
   PubMedGoogle Scholar
• Yamada T, Horiuchi M, Morishita R, Zhang L, Pratt RE, Dzau VJ. In vivo identification of a negative regulatory element in the mouse rennin gene using direct gene transfer. J Clin Invest 1995; 96: 1230–7
   PubMed Web of Science ®Google Scholar
• Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141–5
   PubMed Web of Science ®Google Scholar
• Small W, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997; 44: 217–24
   PubMedGoogle Scholar
• Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998; 352: 179–84
   PubMed Web of Science ®Google Scholar
• Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark. Cancer 2001; 92: 2462–70
   PubMed Web of Science ®Google Scholar
• Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 2002; 82: 747–56
   PubMed Web of Science ®Google Scholar
• Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: Challenging our knowledge of angioedema and its etiology. Laryngoscope 2001; 111: 1729–31
   PubMed Web of Science ®Google Scholar
• Harrap SB, Davidson HR, Watt G. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993; 21: 455–60
   PubMed Web of Science ®Google Scholar